BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)

VOXZOGO® $48 Million Contribution in the Quarter Results in BioMarin Raising Full-year 2022 VOXZOGO Net Product Revenue Guidance to Between $140 Million and...

Related Keywords

Japan ,United States ,Canada ,America ,Debra Charlesworth ,Traci Mccarty ,Jean Jacques Bienaim ,European Commission ,Drug Administration ,Biomarin Pharmaceutical Inc ,Nasdaq ,Replay International Number ,International Number ,Exchange Commission ,Development Expense ,Prnewswire Biomarin Pharmaceutical Inc ,Radiological Health ,European Union Eu Following ,Development Portfolio ,European Medicines Agency ,Biomarin Genzyme ,Quarter Results ,Biomarin Raising Full Year ,Product Revenue Guidance ,Prescription Drug User Fee Act ,Target Action Date ,Commercial Launch ,European Union ,Following August ,Product Revenues Marketed ,Net Product ,Generally Accepted Accounting Principles ,Marin Pharmaceutical ,Chief Executive Officer ,Total Revenues ,Latin America ,Middle East ,Priority Review Voucher ,Product Approvals ,Premarket Approval ,Product Life Cycle Expansion Opportunities ,Hereditary Angioedema ,Duchenne Muscular Dystrophy ,Investigational New Drug ,Year Financial Guidance ,Financial Guidance ,Canada Dial In Number ,Dial In Number ,International Dial In Number ,Biomarin Pharmaceutical ,Net Product Revenues ,Administrative Expense ,Quarterly Report ,Nonqualified Deferred Compensation ,Months Ended September ,Asset Amortization ,Contingent Consideration ,Intangible Asset ,From Income Taxes ,Guidance Year Ending December ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Earnings ,Earnings Forecasts Amp Projections ,